Seaport Therapeutics Inc IPO unlock schedule & public float
Lock-up schedule, public float and locked shares extracted from Seaport Therapeutics Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Shares eligible to trade · by holder groupMay 1, 2026 → Oct 28, 2026 · 100% unlocked
Lock-up holders38.87M
IPO public float14.16M
About Seaport Therapeutics Inc
Seaport Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for cancer and other serious diseases, organized around advancing candidates through preclinical and clinical stages toward regulatory review.
What the company does
Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
Relies on technical, clinical, commercial, and operational teams to move products from development toward broader use.
Business profile
Seaport Therapeutics Inc belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.
SEC IPO filings
Final prospectus
EDGAR filings resolved from SPTX / CIK 0002042347.
Seaport Therapeutics Inc completed its IPO on May 1, 2026 on NASDAQ Global Select under the ticker SPTX and now trades publicly.
What was Seaport Therapeutics Inc's IPO price?
Seaport Therapeutics Inc priced its IPO at $18.00 per share.
Can I buy Seaport Therapeutics Inc stock?
Yes — Seaport Therapeutics Inc is publicly traded on NASDAQ Global Select as SPTX. You can follow its live price, valuation and post-IPO performance above.
What is Seaport Therapeutics Inc's valuation?
Seaport Therapeutics Inc's most recent valuation tracked here is $963.01M, derived from live market prices.
